Cidara Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cidara Therapeutics
CDTX Stock  USD 221.03  0.14  0.06%   
Cidara Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cidara Therapeutics' valuation are provided below:
Gross Profit
-131.8 M
Market Capitalization
7 B
Enterprise Value Revenue
0.6052
Earnings Share
(11.21)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental signals for Cidara Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cidara Therapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 131.1 M in 2026. Enterprise Value is likely to rise to about (17 M) in 2026

Cidara Therapeutics Total Revenue

1.39 Million

Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 378.7 K, Selling General Administrative of 13.2 M or Other Operating Expenses of 214.2 M, as well as many indicators such as Price To Sales Ratio of 126, Dividend Yield of 0.0 or PTB Ratio of 0.99. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Cidara Stock
Check out the analysis of Cidara Therapeutics Correlation against competitors.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Cidara Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities22 M21 M9 M
Slightly volatile
Total Current Liabilities59.8 M57 M25.2 M
Slightly volatile
Cash229.2 M218.3 M72.9 M
Slightly volatile
Cash And Short Term Investments229.2 M218.3 M72.9 M
Slightly volatile
Common Stock Shares Outstanding7.7 M7.3 M2.3 M
Slightly volatile
Total Liabilities33.2 M59.2 M28.5 M
Slightly volatile
Total Current Assets254.5 M242.3 M82.3 M
Slightly volatile
Common Stock1.1 K1.1 K2.7 K
Slightly volatile
Total Assets259.4 M247 M84.7 M
Slightly volatile
Short and Long Term Debt Total5.2 M3.2 M5.8 M
Very volatile
Accounts Payable2.7 M4.1 M2.1 M
Slightly volatile
Non Current Assets Total2.8 M4.7 M2.2 M
Slightly volatile
Non Currrent Assets Other104.9 K110.4 K495.8 K
Slightly volatile
Liabilities And Stockholders Equity259.4 M247 M84.7 M
Slightly volatile
Non Current Liabilities Total2.1 M2.2 M5.6 M
Slightly volatile
Other Current Assets23.2 M22.1 M6.7 M
Slightly volatile
Other Stockholder Equity935.3 M890.7 M311.8 M
Slightly volatile
Other Liabilities22.2 M21.2 M9.4 M
Slightly volatile
Property Plant And Equipment Net4.8 M4.6 M2 M
Slightly volatile
Property Plant And Equipment Gross8.8 M8.4 M3 M
Slightly volatile
Property Plant Equipment189.8 K199.8 K794 K
Slightly volatile
Common Stock Total Equity8.5 K8.1 K3.8 K
Slightly volatile
Capital Surpluse293.1 M464.7 M269.6 M
Slightly volatile
Non Current Liabilities Other24.8 M23.6 M8.4 M
Slightly volatile
Net Receivables1.9 M1.9 M2.8 M
Slightly volatile
Long Term Debt Total6.8 M6.5 M8.2 M
Slightly volatile
Short and Long Term Debt2.2 M2.3 M6.7 M
Slightly volatile
Short Term Debt1.4 M1.5 M6.5 M
Slightly volatile
Current Deferred Revenue15.4 M28.9 M12.2 M
Slightly volatile
Capital Stock1.1 K1.1 K3.5 K
Pretty Stable
Capital Lease Obligations2.7 M4.1 M2.2 M
Slightly volatile

Cidara Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative13.2 M23.7 M11.5 M
Slightly volatile
Other Operating Expenses214.2 M204 M70.1 M
Slightly volatile
Research Development189.3 M180.3 M57.9 M
Slightly volatile
Total Operating Expenses214.2 M204 M67.9 M
Slightly volatile
Non Recurring1.3 M1.4 M1.6 M
Slightly volatile
Preferred Stock And Other Adjustments2.4 M2.5 M6.7 M
Slightly volatile
Interest Income7 M6.7 M1.7 M
Slightly volatile

Cidara Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Non Cash Items3.7 M3.6 M1 M
Slightly volatile
End Period Cash Flow236.9 M225.6 M70.5 M
Slightly volatile
Stock Based Compensation3.9 M4.5 M3 M
Slightly volatile
Begin Period Cash Flow49.5 M41.1 M37.1 M
Slightly volatile
Change To Netincome3.9 M4.1 M3.3 M
Slightly volatile
Issuance Of Capital Stock407.3 M387.9 M77.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12612026.232
Slightly volatile
Days Sales Outstanding458436111
Slightly volatile
Stock Based Compensation To Revenue2.92.760.6866
Slightly volatile
Payables Turnover22.2321.176.3906
Slightly volatile
Sales General And Administrative To Revenue15.2814.553.296
Slightly volatile
Research And Ddevelopement To Revenue53.2850.7411.2905
Slightly volatile
Capex To Revenue0.09560.09110.0194
Slightly volatile
Cash Per Share32.6634.3877.4243
Pretty Stable
Days Payables Outstanding16.9517.841.6 K
Slightly volatile
Income Quality0.660.940.816
Slightly volatile
Current Ratio5.174.894.1901
Very volatile
Receivables Turnover0.820.871.2 K
Slightly volatile
Capex Per Share0.02220.02347.2916
Slightly volatile
Revenue Per Share0.220.2311.6547
Slightly volatile
Interest Debt Per Share0.620.6524.5574
Slightly volatile
Debt To Assets0.01820.01911.7976
Slightly volatile
Days Of Payables Outstanding16.9517.841.6 K
Slightly volatile
Ebt Per Ebit1.081.111.0372
Slightly volatile
Long Term Debt To Capitalization0.120.10764.1876
Slightly volatile
Quick Ratio5.194.894.2028
Very volatile
Net Income Per E B T1.251.151.0912
Slightly volatile
Cash Ratio4.944.413.9828
Very volatile
Days Of Sales Outstanding458436111
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0595
Slightly volatile
Fixed Asset Turnover0.350.3711.1473
Very volatile
Debt Ratio0.01820.01911.7976
Slightly volatile
Price Sales Ratio12612026.232
Slightly volatile
Asset Turnover0.00510.00530.3653
Very volatile

Cidara Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap131.1 M196.3 M143.4 M
Slightly volatile

Cidara Fundamental Market Drivers

Forward Price Earnings5.7504
Cash And Short Term Investments189.8 M

Cidara Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue28.9 M15.4 M
Total Revenue1.5 M1.4 M
Cost Of Revenue97.6 M102.5 M
Stock Based Compensation To Revenue 2.76  2.90 
Sales General And Administrative To Revenue 14.55  15.28 
Research And Ddevelopement To Revenue 50.74  53.28 
Capex To Revenue 0.09  0.10 
Revenue Per Share 0.23  0.22 
Ebit Per Revenue(158.84)(150.90)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY